• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma
【24h】

Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma

机译：造血祖细胞移植治疗复发性或难治性霍奇金淋巴瘤

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Advanced-stage Hodgkin's lymphoma (HL) has become a curable disease in the majority of patients. Despite this, about 20% of these patients relapsed or are primary refractory to the first-line treatment and high-dose chemotherapy (HDC) and autologous (Auto) hematopoietic progenitor cells transplantation (HPCT) are considered a therapeutic option. Areas covered: The authors reviewed HDC and HPCT treatment strategies in recurrent or refractory HL patients, with the goal of providing an overview of this approach. Expert opinion: Patients younger than 60-65 years with relapsed disease or refractory to first-line therapy should receive a second-line chemotherapy, followed by HDC and Auto-HPCT. Progression-free and overall survival results are significantly better when a second remission or a minimal disease status is achieved before Auto-HPCT, and demonstrate that this strategy is able to cure more than half of the advanced HL patients. Myeloablative allogeneic HPCT (Allo-HPCT) has been employed in advanced phases of the disease, but there have been significant concerns due to treatment-related mortality (TRM). The safety of allogeneic transplantation has improved with the use of reduced-intensity allogeneic (RIC-Allo) HPCT strategies. Despite early favorable results, mature results of RIC-Allo available in the literature are consistent in demonstrating a lack of long-term disease control.
机译：简介：晚期霍奇金淋巴瘤（HL）已成为大多数患者可治愈的疾病。尽管如此，这些患者中约有20％复发或对一线治疗无效，并且大剂量化疗（HDC）和自体（Auto）造血祖细胞移植（HPCT）被认为是治疗选择。研究范围：作者回顾了复发性或难治性HL患者的HDC和HPCT治疗策略，目的是对该方法进行概述。专家意见：年龄小于60-65岁的复发性疾病或一线治疗难治的患者应接受二线化疗，然后进行HDC和Auto-HPCT。当在Auto-HPCT之前达到第二次缓解或最低疾病状态时，无进展和总体生存结果会明显更好，并证明该策略能够治愈一半以上的晚期HL患者。异化性同种异体HPCT（Allo-HPCT）已用于疾病的晚期，但是由于与治疗相关的死亡率（TRM），引起了人们的极大关注。通过使用强度降低的异基因（RIC-Allo）HPCT策略，异基因移植的安全性得到了提高。尽管取得了早期的良好结果，但文献中可获得的RIC-Allo的成熟结果一致表明缺乏长期的疾病控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号